Halozyme licenses its ENHANZE enzyme technology to pharma giants, letting their injectable drugs be given as quick under-the-skin shots instead of slow IV drips. Think of it as a delivery unlock for other companies' medicines.
Money comes from royalty and milestone payments tied to partners' drug sales, plus its own Hylenex product. Gross margin is 78%, and revenue grew from USD 0.83B in 2023 to USD 1.40B in 2025, with recurring royalty streams.
Its patented rHuPH20 enzyme is embedded in blockbuster drugs from Roche, Pfizer, Janssen, and AbbVie, making it costly for them to switch. But the moat is eroding as patents expire and competitors like Alteogen develop rival hyaluronidase platforms.
Strong Buy (sector percentile 88) — value B, growth A-, profitability A+, momentum B+, revisions B+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Multiple sources report Q2 beat and raised outlook, stock up, but no new facts, just repetition.
Grants ENHANZE rights to support subcutaneous cancer therapy development
2026年至2028年调整后EBITDA利润率预计超过65%，并接近70%。
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
